Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation

Details

Serval ID
serval:BIB_9B925665FAA8
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Efficacy of amiodarone in the Wolff-Parkinson-White syndrome with rapid ventricular response via accessory pathway during atrial fibrillation
Journal
American Journal of Cardiology
Author(s)
Kappenberger  L. J., Fromer  M. A., Steinbrunn  W., Shenasa  M.
ISSN
0002-9149 (Print)
Publication state
Published
Issued date
08/1984
Volume
54
Number
3
Pages
330-5
Notes
Journal Article --- Old month value: Aug 1
Abstract
Sudden death in Wolff-Parkinson-White syndrome (WPW) is related to a very fast ventricular response to spontaneous atrial fibrillation (AF) conducted via accessory pathway (AP). The effect of oral amiodarone was studied in 12 patients with WPW syndrome and life-threatening rapid ventricular response via an AP during spontaneous AF. The effective refractory period of the AP in the anterograde direction was 280 ms or less during control study in all patients. After amiodarone therapy, the effective refractory period remained 280 ms or less in 7 of the 12 patients. During incremental atrial pacing, the longest atrial pacing cycle length that produced block over an AP ranged from 200 to 310 ms (mean 261 +/- 42) during the control period and 240 to 980 ms (mean 377 +/- 198) after amiodarone therapy. During AF the shortest ventricular response via the AP could be measured in 10 of 12 of the patients both before and after amiodarone treatment and ranged from 200 to 290 ms (234 +/- 30) and 250 to 500 (mean 302 +/- 75), respectively (p less than 0.01). The average RR interval during AF before and after the drug ranged from 200 to 390 ms (mean 280 +/- 55) and 280 to 650 ms (mean 396 +/- 116), respectively (p less than 0.01). Thus, the safety of amiodarone in the WPW syndrome should be established by electrophysiologic studies and induction of AF, because amiodarone is not protective in all patients with WPW.
Keywords
Adolescent Adult Amiodarone/*therapeutic use Atrial Fibrillation/drug therapy/etiology Benzofurans/*therapeutic use Cardiac Pacing, Artificial Electrocardiography Female Heart Conduction System/*physiopathology Humans Male Middle Aged Prospective Studies Tachycardia/drug therapy Wolff-Parkinson-White Syndrome/complications/*drug therapy/physiopathology
Pubmed
Web of science
Create date
15/02/2008 11:29
Last modification date
20/08/2019 15:02
Usage data